Koron Pharmaceutical (002422.SZ): The Phase III clinical study of the combination of Lusutuzumab vedotin (sac-TMT) and Pembrolizumab as first-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer with negative PD-L1 achieved the primary endpoint.

Zhtng Cijng APP Xn, K ln yoy (002422.SZ) fb gnggo, gngs kngg zgngs k ln b ti b xingrn zyng xbo biomin kngy q tng 2 (TROP2) de kngt ulin yow (ADC) l kng sh tu zh dn kng (sac-TMT) (ji ti li ) linh m sh dng de kng chngxng x bo s wng dn bi -1 (PD-1) dn k kung yo p b l zh dn kng (k ru d ) yxin zhl chngxng x bo s wng pi t-1 (PD-L1) yng xng de jb wnq hu zhunyxng fi qun zhung fi xio x bo fi'i (NSCLC) de 3 q lnghi ynji (OptiTROP-Lung06), zi y sh de qzhng fnx zhng, jng dl dt jinch wiyunhu (IDMC) qurn ddo w jnzhn shngcn q (PFS) zhyo zhngdin.